By Neetha Mahadevan
FRANKFURT--German pharmaceutical company Bayer AG said Thursday
it is suspending enrollment into a Phase III trial for its
Regorafenib drug for the treatment of colorectal cancer patients
due to insufficient patient recruitment.
Regorafenib, also known as Stivarga, was to have been examined
for the treatment of colorectal cancer patients following resection
of liver metastases. It has already been approved in various
countries, including the U.S., Europe and Japan, for the treatment
of metastatic colorectal cancer, as well as to treat patients with
gastrointestinal stromal tumors.
The study will be closed to further enrolment before the study
endpoints can be assessed, Bayer said.
Regorafenib is a compound developed by Bayer and has an
agreement with Onyx Pharmaceuticals Inc., an Amgen subsidiary,
under which Onyx receives a royalty on all global net sales of
regorafenib in oncology.
Write to Neetha Mahadevan at Neetha.Mahadevan@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires